How are key demographic indicators related to COVID-19 reported in the United States: A data review protocol—Study description

The COVID-19 pandemic is evolving fast and affecting rich and poor countries; however, the social determinants of the health outcomes associated with COVID-19 have not been well characterized. While there is increasing discussion of COVID-19 disparities in the media, no systematic compilation of data exists that synthesizes what and how official reporting platforms disaggregate demographic indicators of COVID-19 testing, cases, hospitalizations, recoveries and deaths. This review will provide a comprehensive overview of what and how federal and local health officials report COVID-19 cases. Having this information nationally and subnationally can help health officials to deploy a more targeted response effort such as testing, treatment, and contact tracing. This information could be useful for future vaccine development. This data review can reveal gaps in our public health data system, which can lead to recommendations on how to improve data standardization, disaggregation, and reporting, particularly for tracking outbreaks. This protocol may be replicated in other countries to understand how demographic indicators are being reported and their relationship to COVID-19 health outcomes

“I don’t bother with the phone!”: Feeling Closer to Physician using Secure Messaging

This study explores the use of phone and secure messaging via an online patient portal in mediating the communication between patients and their healthcare providers. In analyzing the messages handling processes, we found that although both phone and secure messages were answered in similar manners, the interplay of the front- and back-end roles in collaborative work resulted in patients’ preference for secure messages in communication as they believed it offered direct and empowered communication experiences. This study offers insights on the choice of how different communication media affect patients’ perception toward the quality of the communication and patient-provider relationship.

Tracking COVID-19 data reporting and analysis in the United States: Findings from December, August, and May 2020

Throughout the course of the pandemic, Population Council researchers have been tracking how COVID-19 data is reported and analyzed using a comprehensive analysis of 62 COVID-19 data sources from the Centers for Disease Control and Prevention (CDC) and health departments across 50 states and the District of Columbia (DC), and ten cities. We assessed data completeness for COVID-19 testing and four outcomes (cases, hospitalizations, recoveries, and deaths), and examined disaggregation of COVID-19 testing and outcomes by a core set of demographic indicators, including age, race/ethnicity, sex/gender, geography, and underlying health conditions. This analysis also investigated how social and community level data were reported and analyzed, variations in data reporting, and changes over the course of the pandemic by comparing data across three time points: May, August and December, 2020

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

BACKGROUND: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values, for the non-invasive diagnosis of steatosis in patients with or without chronic liver disease. Biomarkers and panels were assessed in a training group of consecutive patients with chronic hepatitis C and B, alcoholic liver disease, and non-alcoholic fatty liver disease, and were validated in two independent groups including a prospective one. Steatosis was blindly assessed by using a previously validated scoring system. RESULTS: 310 patients were included in the training group; 434 in three validation groups; and 140 in a control group. SteatoTest was constructed using a combination of the 6 components of FibroTest-ActiTest plus body mass index, serum cholesterol, triglycerides, and glucose adjusted for age and gender. SteatoTest area under the ROC curves was 0.79 (SE = 0.03) in the training group; 0.80 (0.04) in validation group 1; 0.86 (0.03) in validation group 2; and 0.72 (0.05) in the validation group 3 – all significantly higher than the standard markers: γ-glutamyl-transpeptidase or alanine aminotransferase. The median SteatoTest value was 0.13 in fasting controls; 0.16 in non-fasting controls; 0.31 in patients without steatosis; 0.39 in grade 1 steatosis (0–5%); 0.58 in grade 2 (6–32%); and 0.74 in grade 3–4 (33–100%). For the diagnosis of grade 2–4 steatosis, the sensitivity of SteatoTest at the 0.30 cut-off was 0.91, 0.98, 1.00 and 0.85 and the specificity at the 0.70 cut-off was 0.89, 0.83, 0.92, 1.00, for the training and three validation groups, respectively. CONCLUSION: SteatoTest is a simple and non-invasive quantitative estimate of liver steatosis and may reduce the need for liver biopsy, particularly in patients with metabolic risk factor

A brain-targeting lipidated peptide for neutralizing RNA-mediated toxicity in Polyglutamine Diseases

Abstract Polyglutamine (PolyQ) diseases are progressive neurodegenerative disorders caused by both protein- and RNA-mediated toxicities. We previously showed that a peptidyl inhibitor, P3, which binds directly to expanded CAG RNA can inhibit RNA-induced nucleolar stress and suppress RNA-induced neurotoxicity. Here we report a N-acetylated and C-amidated derivative of P3, P3V8, that showed a more than 20-fold increase in its affinity for expanded CAG RNA. The P3V8 peptide also more potently alleviated expanded RNA-induced cytotoxicity in vitro, and suppressed polyQ neurodegeneration in Drosophila with no observed toxic effects. Further N-palmitoylation of P3V8 (L1P3V8) not only significantly improved its cellular uptake and stability, but also facilitated its systemic exposure and brain uptake in rats via intranasal administration. Our findings demonstrate that concomitant N-acetylation, C-amidation and palmitoylation of P3 significantly improve both its bioactivity and pharmacological profile. L1P3V8 possesses drug/lead-like properties that can be further developed into a lead inhibitor for the treatment of polyQ diseases

LOS COCHINOS [Material gráfico]

Acuarela de José Hurtado de Mendoza. Propiedad de Caridad Rodríguez Pérez-Galdós.Finca de cochinos en La Aldea de San Nicolás.Copia digital. Madrid : Ministerio de Educación, Cultura y Deporte. Subdirección General de Coordinación Bibliotecaria, 201

SEDATIVE AND ANTICONVULSANT PROPERTIES OF PASSIFLORA EDULIS DRIED LEAVES DECOCTION IN MICE

Passiflora edulis Sims is native from Tropical area of South America. It is used in traditional medicine in the treatment of some diseases related to the nervous system and others. The extract of Passiflora edulis possesses sedative activity in mice. It significantly increased the total sleep time induced by diazepam (50 mg/kg i.p.). The total sleep time increased from 31 + 11 min in the control group to 77.6 + 15 and 78.3 + 16 min in the groups treated with extract at the doses of 132.5 and 1325 mg/kg respectively. This extract showed also anticonvulsant activity in mice. It protected mice against strychnine -induced seizures and antagonized N-methyl-D-aspartate- induced turning behavior in mice. The ED50 for the protection against seizures -induced by strychnine was 320 mg/kg intraperitoneally (i.p.). For N-methyl-D-aspartate -induced turning behavior, the ED50 was 300 mg/kg i.p. Passiflora edulis extract had less effect against pentylene tetrazol- induced seizures. The potentiation of diazepam-induced sleep, the antagonism of chemical -induced seizures and turning behavior suggest that Passiflora edulis extract possess sedative and anticonvulsant properties in animals

Challenges and opportunities for implementing integrated mental health care: a district level situation analysis from five low- and middle-income countries.

BACKGROUND: Little is known about how to tailor implementation of mental health services in low- and middle-income countries (LMICs) to the diverse settings encountered within and between countries. In this paper we compare the baseline context, challenges and opportunities in districts in five LMICs (Ethiopia, India, Nepal, South Africa and Uganda) participating in the PRogramme for Improving Mental health carE (PRIME). The purpose was to inform development and implementation of a comprehensive district plan to integrate mental health into primary care. METHODS: A situation analysis tool was developed for the study, drawing on existing tools and expert consensus. Cross-sectional information obtained was largely in the public domain in all five districts. RESULTS: The PRIME study districts face substantial contextual and health system challenges many of which are common across sites. Reliable information on existing treatment coverage for mental disorders was unavailable. Particularly in the low-income countries, many health service organisational requirements for mental health care were absent, including specialist mental health professionals to support the service and reliable supplies of medication. Across all sites, community mental health literacy was low and there were no models of multi-sectoral working or collaborations with traditional or religious healers. Nonetheless health system opportunities were apparent. In each district there was potential to apply existing models of care for tuberculosis and HIV or non-communicable disorders, which have established mechanisms for detection of drop-out from care, outreach and adherence support. The extensive networks of community-based health workers and volunteers in most districts provide further opportunities to expand mental health care. CONCLUSIONS: The low level of baseline health system preparedness across sites underlines that interventions at the levels of health care organisation, health facility and community will all be essential for sustainable delivery of quality mental health care integrated into primary care